Targeted Approaches to T-Cell Lymphoma

被引:1
|
作者
Harrop, Sean [1 ]
Abeyakoon, Chathuri [2 ]
Van der Weyden, Carrie [1 ]
Prince, H. Miles [1 ,3 ,4 ]
机构
[1] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia
[2] Monash Hlth, Melbourne, Vic 3168, Australia
[3] Epworth Healthcare, Melbourne, Vic 3002, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic 3000, Australia
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 06期
关键词
novel agents; monoclonal antibodies; immunotherapy; NON-HODGKIN-LYMPHOMA; BRENTUXIMAB VEDOTIN; PHASE-II; MYCOSIS-FUNGOIDES; OPEN-LABEL; CD30; EXPRESSION; SEZARY-SYNDROME; PI3K-DELTA; GAMMA INHIBITOR; MONOCLONAL-ANTIBODY; PHYSICIANS CHOICE;
D O I
10.3390/jpm11060481
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The T-cell lymphomas are a rare group of Non-Hodgkin's lymphomas derived from mature T-lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the Cutaneous T-cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The development of an understanding of the various critical pathways in T-cell lymphogenesis and subsequent identification of therapeutic targets has led to a rapid expansion of the previously underwhelming T-cell lymphoma armament. This review aims to provide an up-to-date overview of the current state of targeted therapies in the T-cell lymphomas, including novel antibody-based treatments, small molecule inhibitors and immune-based therapies.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] T-cell therapies for T-cell lymphoma
    Toner, Keri
    Bollard, Catherine M.
    Dave, Hema
    CYTOTHERAPY, 2019, 21 (09) : 935 - 942
  • [2] Emerging drugs for the treatment of cutaneous T-cell lymphoma
    Cheng, Melissa
    Zain, Jasmine
    Rosen, Steven T.
    Querfeld, Christiane
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (01) : 45 - 54
  • [3] Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma
    Van-de-Velde, Vanessa
    Zhou, Youwen
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2019, 23 (03) : 319 - 327
  • [4] Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma
    Pelcovits, Ari
    Ollila, Thomas A.
    Olszewski, Adam J.
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 989 - 998
  • [5] Brentuximab vedotin in T-cell lymphoma
    Van der Weyden, Carrie
    Dickinson, Michael
    Whisstock, James
    Prince, H. Miles
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (01) : 5 - 19
  • [6] T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment
    Casulo, Carla
    O'Connor, Owen
    Shustov, Andrei
    Fanale, Michelle
    Friedberg, Jonathan W.
    Leonard, John P.
    Kahl, Brad S.
    Little, Richard F.
    Pinter-Brown, Lauren
    Advani, Ranjani
    Horwitz, Steven
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (02):
  • [7] Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents
    Devata, Sumana
    Wilcox, Ryan A.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2016, 17 (03) : 225 - 237
  • [8] Peripheral T-Cell Lymphoma Moving Toward Targeted Therapies
    Ng, Samuel Y.
    Jacobsen, Eric D.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2019, 33 (04) : 657 - +
  • [9] Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma
    Ion, Alexandra
    Popa, Iris Maria
    Papagheorghe, Laura Maria Lucia
    Lisievici, Cristina
    Lupu, Mihai
    Voiculescu, Vlad
    Caruntu, Constantin
    Boda, Daniel
    DISEASE MARKERS, 2016, 2016 : 1 - 8
  • [10] Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
    Chen, Xi
    Wu, Wanchun
    Wei, Wenwen
    Zou, Liqun
    FRONTIERS IN PHARMACOLOGY, 2022, 13